SXTP 60 Degrees Pharma Total Asset Value of Company

This price trend visualization for the total assets of 60 Degrees Pharmaceuticals (SXTP), valued at 4.50, reflects the dynamics of the biotech business. The company's revenues are based on the sale of an anti-malarial drug, targeting government contracts and the tourism sector. Simultaneously, 60 Degrees Pharmaceuticals (SXTP) is implementing eco-friendly production and packaging methods, developing a pipeline of new antiviral drugs, and expanding clinical trials for tafenoquine.

SXTP (60 Degrees Pharmaceuticals, Inc.) Company Total Assets history from 02/21/2024 to 10/31/2026

Analytical breakdowns and data insights for company 60degreespharma.com (SXTP)

- current price and projected stock value:

Quote Chart 60 Degrees Pharmaceuticals, Inc.|SXTP - Price Target Chart

- market capitalization data:

Market Valuation 60 Degrees Pharmaceuticals, Inc.|SXTP - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share 60 Degrees Pharmaceuticals|SXTP - Book Capitalization|Market Capitalization to Book Value Ratio 60degreespharma.com|SXTP - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio 60 Degrees Pharmaceuticals|SXTP - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio 60 Degrees Pharmaceuticals, Inc.|SXTP - Company Aggregate Debts|Debts to Book Capitalization 60 Degrees Pharmaceuticals, Inc.|SXTP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings 60 Degrees Pharmaceuticals|Interim Coverage Ratio 60degreespharma.com

- net income and valuation multiples indicators:

SXTP - Company Net Income

Fundamental valuation:60 Degrees Pharmaceuticals

Manufactured products of 60 Degrees Pharmaceuticals Inc.

Reverse calculation via ROA enables daily tracking of the total value of resources combining equity and liabilities, which eliminates the lag between quarterly reports and reveals the actual strength of the balance sheet. For 60 Degrees Pharmaceuticals (SXTP), these total assets reflect the capacity to scale the production of antimalarial drugs for government contracts and defense department needs, where any stagnation in the curve signals underinvestment risks.

Key competitors

Total Asset Value of Company SMMT (summittxinc.com)|Aggregate Company Assets Moderna|Vaxcyte Inc - Total Asset Value of Company|Company Total Assets TARS|CRMD (CorMedix Therapeutics) - Aggregate Asset Value|Company Total Assets MCRB (Seres Therapeutics)|Company Total Assets sperotherapeutics.com SPRO|SCYX - Aggregate Company Assets|Aggregate Asset Value ANTX (AN2 Therapeutics, Inc.)|polypid.com (PYPD) - Aggregate Company Assets|Cumulative Company Assets YS Biopharma Co., Ltd.|ITRM (Iterum Therapeutics PLC) - Company Total Assets|Company Total Assets BiomX Ltd|Cumulative Company Assets SNGX (Soligenix, Inc.)|OGEN (oragenics.com) - Aggregate Asset Value|Company Total Assets ONCO (Onconetix Corp)|Company Total Asset Base OpGen Corporation (OPGN)